Page last updated: 2024-12-05
stenopril
Description
Stenopril (also known as telmisartan) is an angiotensin II receptor blocker (ARB) used to treat high blood pressure. It works by blocking the action of angiotensin II, a hormone that narrows blood vessels. This helps lower blood pressure and reduce the risk of stroke, heart attack, and other cardiovascular problems. Telmisartan is synthesized through a multi-step process involving several organic reactions, such as the formation of a tetrazole ring and a benzimidazole ring. Its effects are primarily attributed to its ability to block the AT1 receptor, which is responsible for mediating the effects of angiotensin II. Telmisartan is studied extensively due to its clinical benefits in managing hypertension and its potential application in other cardiovascular diseases. It is also being investigated for its potential role in preventing kidney disease, reducing the risk of dementia, and improving metabolic syndrome.'
stenopril: RN given refers to parent cpd; stenopril refers to the HCl [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
PubMed CID | 5025 |
SCHEMBL ID | 18645287 |
MeSH ID | M0087897 |
Synonyms (13)
Synonym |
benzenepropanamine, n-(1-methyl-2-phenylethyl)- |
alpha-methyl-n-(3-phenylpropyl)phenethylamine |
stenopril |
13005-65-7 |
1-phenyl-n-(3-phenylpropyl)propan-2-amine |
AKOS005359132 |
cas_131443 |
bdbm85392 |
nsc_131443 |
ppap, (-) |
SCHEMBL18645287 |
3-phenyl-n-(1-phenylpropan-2-yl)propan-1-amine |
DTXSID80926577 |
Research
Studies (4)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 3 (75.00) | 18.7374 |
1990's | 1 (25.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.38
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 12.38 (24.57) | Research Supply Index | 1.95 (2.92) | Research Growth Index | 4.32 (4.65) | Search Engine Demand Index | 0.00 (26.88) | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |